Vitamin D treatment not found to reduce cardiovascular abnormalities in kidney disease patients

February 14, 2012, Massachusetts General Hospital

Almost a year's treatment with a vitamin D compound did not alleviate key structural and functional cardiovascular abnormalities in patients with kidney disease and cardiac enlargement. In a paper in the February 15 Journal of the American Medical Association, an international research team reports that daily doses of a vitamin D compound did not reduce enlargement or improve impaired functioning of the heart's main pumping chamber.

"Several studies have suggested that vitamin D therapy may improve , so we were surprised that the results did not support our hypothesis that paricalcitol, which we use to treat hyperparathyroidsm in kidney disease patients, would reduce left ventricular and improve diastolic function in these patients," says Ravi Thadhani, MD, MPH, of the Massachusetts General Hospital Division of Nephrology, lead author of the JAMA report. "There was some evidence that paricalcitol may reduce the incidence of heart failure, but that will need to be followed up in a larger trial focused on that potential outcome."

Patients with become deficient in vitamin D, which leads to elevated hormone (PTH) levels, commonly treated with paricalcitol. Since kidney disease patients are at increased risk of cardiovascular disease, which may be associated with , the current study was designed to investigate the impact of paricalcitol treatment on specific cardiovascular abnormalities.

The PRIMO (Paricalcitol capsule benefits in Renal-failure-Induced MOrbidity) study enrolled 227 participants from 60 centers in 11 countries, all of whom had chronic kidney disease and mild to moderate enlargement of the . Participants – whose PTH levels had just reached the point where paricalcitol could be prescribed – were randomly assigned to receive daily doses of either paricalcitol or a placebo for 48 weeks. Changes in the size of the left ventricle were measured by cardiac MRI, and ventricular function was assessed by echocardiography and MRI.

At the end of the study period, participants receiving paricalcitol did have lower PTH levels, but there was no significant difference between the two groups in either left ventricular enlargement or in echocardiographic measures of ventricular function. Fewer members of the paricalcitol group were hospitalized for cardiovascular disease, and those participants also had lower blood levels of a biomarker for heart failure; but the study was not large enough to confirm a reduced risk of heart failure with paricalcitol treatment.

"The study did not support our hypothesis but presented us with two intriguing findings," says Scott Solomon, MD, director of Noninvasive Cardiology at Brigham and Women's Hospital and senior author of the JAMA report. "If the larger outcomes studies that are currently underway confirm a paricalcitol benefit in , our results suggest that the mechanism must be something other than reducing left ventricular hypertrophy or improving diastolic function."

Explore further: Diastolic dysfunction appears to worsen over time; associated with increased risk of heart failure

More information: JAMA. 2012;307[7]:722-723.

Related Stories

Diastolic dysfunction appears to worsen over time; associated with increased risk of heart failure

August 23, 2011
A follow-up of participants in a heart function study finds that the prevalence of left ventricular diastolic dysfunction (left ventricular filling [with blood] is abnormal and is accompanied by elevated filling pressures) ...

A heart-rate-reducing medication reduces the risk of heart failure and cardiac fibrosis

July 28, 2011
The findings of a Montreal Heart Institute (MHI) study published in the scientific journal Cardiology suggest that ivabradine, a heart rate reduction medication, is also effective in reducing the risk of diastolic heart failure ...

Recommended for you

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

Place of residence linked to heart failure risk

January 9, 2018
Location. Location. Location.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

deatopmg
1 / 5 (1) Feb 14, 2012
NOT vitamin D3 but a "vitamin D compound", i.e. patented man made vitamin D like derivative.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.